About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The VHIR Infectious Diseases research group is made up of medical professionals, with healthcare and clinical or basic translational research activities; of Biomedicine dedicated to basic research; and Nursing, with activities to support clinical research.
The group's lines of research are mainly focused on four areas:
Infections related to immunosuppression. Includes infectious diseases related to immunocompromised patients, solid organ or hematopoietic stem cell transplant recipients and recipients of biological therapies.
Sexually transmitted diseases, including HIV infection and other highly prevalent infections in our country (syphilis, gonorrhea, lymphogranuloma venere or infections caused by the human papillomavirus).
Infections related to health care, with special emphasis on those difficult to treat (cardiovascular infections or infections related to prosthetic materials) or caused by multi-resistant pathogens (MDRO) or affecting vulnerable populations.
Global Health and Tropical Diseases with special emphasis on prevalent diseases in our environment that affect the immigrant or displaced population.
PMID: 31977595 Journal: JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES Year: 2020 Reference: J Acquir Immune Defic Syndr. 2020 May 1;84(1):60-65. doi: 10.1097/QAI.0000000000002302. Impact factor: 3.475 Publication type: Paper in international publication Authors: Eron, Joseph, Hung, Chien-Ching, Baril, Jean-Guy, Slim, Jihad, Falco, Vicenc, Bogner, Johannes, Maggiolo, Franco, Mills, Anthony, Sievers, Jorg, Man, Choy Y et al. DOI: 10.1097/QAI.0000000000002302
PMID: 31958020 Journal: EXPERT OPINION ON PHARMACOTHERAPY Year: 2020 Reference: Expert Opin Pharmacother. 2020 Apr;21(6):629-636. doi: 10.1080/14656566.2020.1714592. Epub 2020 Jan 20. Impact factor: 2.878 Publication type: Review in international publication Authors: Falco, Vicenc, Burgos, Joaquin, Almirante, Benito et al. DOI: 10.1080/14656566.2020.1714592
PMID: 31951264 Journal: JOURNAL OF TROPICAL PEDIATRICS Year: 2020 Reference: J Trop Pediatr. 2020 Aug 1;66(4):428-434. doi: 10.1093/tropej/fmz083. Impact factor: 0.94 Publication type: Paper in international publication Authors: Omer, Samia A, Adam, Ishag, Noureldien, Ali, Elhaj, Hadeel, Guerrero-Latorre, Laura, Silgado, Aroa, Sulleiro, Elena, Molina, Israel et al. DOI: 10.1093/tropej/fmz083
PMID: 31926653 Journal: MEDICINA CLINICA Year: 2020 Reference: Med Clin (Barc). 2020 May 8;154(9):351-357. doi: 10.1016/j.medcli.2019.11.002. Epub 2020 Jan 8. Impact factor: 1.635 Publication type: Review in national publication Authors: Escola-Verge, Laura, Los-Arcos, Ibai, Almirante, Benito et al. DOI: 10.1016/j.medcli.2019.11.002
PMID: 30782268 Journal: Eurosurveillance Year: 2019 Reference: Euro Surveill. 2019 Feb;24(7). doi: 10.2807/1560-7917.ES.2019.24.7.1700857. Impact factor: 7.421 Publication type: Review in international publication Authors: Martinez-Gomez, Xavier, Curran, Adrian, Campins, Magda, Alemany, Laia, Rodrigo-Pendas, Jose Angel, Borruel, Natalia, Castellsague, Xavier, Diaz-de-Heredia, Cristina, Moraga-Llop, Fernando A, Del Pino, Marta et al. DOI: 10.2807/1560-7917.ES.2019.24.7.1700857
PMID: 30779771 Journal: PLoS One Year: 2019 Reference: PLoS One. 2019 Feb 19;14(2):e0212426. doi: 10.1371/journal.pone.0212426. eCollection 2019. Impact factor: 2.776 Publication type: Paper in international publication Authors: Basas, Jana, Palau, Marta, Gomis, Xavier, Almirante, Benito, Gavalda, Joan et al. DOI: 10.1371/journal.pone.0212426
PMID: 30738716 Journal: ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA Year: 2019 Reference: Enferm Infecc Microbiol Clin. 2019 Jun - Jul;37(6):398-404. doi: 10.1016/j.eimc.2018.12.009. Epub 2019 Feb 7. Impact factor: 1.685 Publication type: Paper in national publication Authors: Arando Lasagabaster, Maider, Otero Guerra, Luis et al. DOI: 10.1016/j.eimc.2018.12.009
PMID: 30738196 Journal: Travel Medicine and Infectious Disease Year: 2019 Reference: Travel Med Infect Dis. 2019 May - Jun;29:51-57. doi: 10.1016/j.tmaid.2019.02.001. Epub 2019 Feb 6. Impact factor: 4.868 Publication type: Paper in international publication Authors: Molina, Israel, Henriquez-Camacho, Cesar, Serre, Nuria, Norman, Francesca, Wilkman-Jorgensen, Philip, Torrus, Diego, Ramos Rincon, Jose Manuel, Malmierca, Eduardo, Perez-Ayala, Ana, Herrero, Juan Maria et al. DOI: 10.1016/j.tmaid.2019.02.001
The new protocol has the same efficacy as the standard one, but only a quarter of the duration, reducing dropout rates and side effects.
The initiative, carried out at the Consulate of Bolivia, has resulted in 307 new tests for the diagnosis of Chagas disease
The study shows that blocking the KLRG1 receptor helps to recover the activity of the natural killer cells of the immune system and reactivate the virus reservoir to fight infection.
